ECSP23020167A - Inhibidores de apol1 y métodos para usar los mismos - Google Patents
Inhibidores de apol1 y métodos para usar los mismosInfo
- Publication number
- ECSP23020167A ECSP23020167A ECSENADI202320167A ECDI202320167A ECSP23020167A EC SP23020167 A ECSP23020167 A EC SP23020167A EC SENADI202320167 A ECSENADI202320167 A EC SENADI202320167A EC DI202320167 A ECDI202320167 A EC DI202320167A EC SP23020167 A ECSP23020167 A EC SP23020167A
- Authority
- EC
- Ecuador
- Prior art keywords
- apol1
- methods
- inhibitors
- tautomer
- ndkd
- Prior art date
Links
- 102100030762 Apolipoprotein L1 Human genes 0.000 title abstract 2
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 abstract 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 abstract 2
- 208000038001 non-diabetic kidney disease Diseases 0.000 abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070705P | 2020-08-26 | 2020-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23020167A true ECSP23020167A (es) | 2023-12-29 |
Family
ID=77822053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202320167A ECSP23020167A (es) | 2020-08-26 | 2023-03-20 | Inhibidores de apol1 y métodos para usar los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11866446B2 (https=) |
| EP (1) | EP4204423A1 (https=) |
| JP (2) | JP7743504B2 (https=) |
| KR (1) | KR20230057386A (https=) |
| CN (1) | CN116547287B (https=) |
| AR (1) | AR123355A1 (https=) |
| AU (1) | AU2021333776A1 (https=) |
| BR (1) | BR112023003423A2 (https=) |
| CA (1) | CA3190609A1 (https=) |
| CL (1) | CL2023000536A1 (https=) |
| CO (1) | CO2023003026A2 (https=) |
| CR (1) | CR20230132A (https=) |
| DO (1) | DOP2023000042A (https=) |
| EC (1) | ECSP23020167A (https=) |
| IL (2) | IL318169A (https=) |
| JO (1) | JOP20230035A1 (https=) |
| MX (1) | MX2023002269A (https=) |
| PE (1) | PE20231106A1 (https=) |
| SA (1) | SA523442662B1 (https=) |
| UY (1) | UY39395A (https=) |
| WO (1) | WO2022047031A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN116547287B (zh) * | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US20230119114A1 (en) * | 2021-08-26 | 2023-04-20 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitors and methods of using same |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| CA3251050A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE |
| WO2024249252A1 (en) * | 2023-05-26 | 2024-12-05 | Maze Therapeutics, Inc. | Methods of using apol1 inhibitors |
| AU2024343017A1 (en) | 2023-09-11 | 2026-03-19 | Vertex Pharmaceuticals Incorporated | Process for preparing (2s,4s,4's,6s)-2-methyl-6-(1-methyl-1h-1,2,3-triazol-4-yl)-2',-(trieluoromethyl)-4',5'-dihydrospiro[piperidine-4,7'-thieno [2,3-c] pyran] -4'-ol |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039676A (en) | 1975-06-23 | 1977-08-02 | Ciba-Geigy Corporation | 2-piperidinoalkyl-1,4-benzodioxans |
| US6518423B1 (en) | 1996-08-09 | 2003-02-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
| AU7514700A (en) | 1999-09-07 | 2001-04-10 | Syngenta Participations Ag | Cyanopiperidines |
| FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| AU2002211828A1 (en) | 2000-10-02 | 2002-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| FR2824827B1 (fr) | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| FR2824826B1 (fr) | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
| US20030119060A1 (en) | 2001-08-10 | 2003-06-26 | Desrosiers Peter J. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| WO2003104180A1 (en) | 2002-06-05 | 2003-12-18 | Natco Pharma Limited | Process for the preparation of 4-(4-fluorobenzoyl) butyric acid |
| JP2007504221A (ja) | 2003-09-03 | 2007-03-01 | ガラパゴス・エヌブイ | 新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用 |
| BRPI0507657A (pt) | 2004-03-03 | 2007-07-10 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
| AR048523A1 (es) | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| JP5406722B2 (ja) | 2006-10-16 | 2014-02-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体 |
| BRPI0721138A2 (pt) | 2006-12-22 | 2014-04-01 | Hoffmann La Roche | Derivados de espiro-piperidina |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| DK2178870T3 (en) | 2007-08-17 | 2018-10-22 | Lg Chemical Ltd | INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE |
| CN105254557A (zh) | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| UA107943C2 (xx) | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| AU2010319400B2 (en) | 2009-11-16 | 2013-12-19 | Eli Lilly And Company | Spiropiperidine compounds as ORL-1 receptor antagonists |
| WO2012025155A1 (en) | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| BR102012024778A2 (pt) | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
| EP3186225A4 (en) | 2014-08-27 | 2018-02-28 | The Governing Council of the University of Toronto | Cannabinoid type 1 receptor modulators |
| US10654838B2 (en) | 2014-10-08 | 2020-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Aminopyridine compounds useful as inhibitors of protein prenylation |
| JP2017535545A (ja) | 2014-11-21 | 2017-11-30 | ラボラトリオス・デル・デエレ・エステベ・エセ・ア | 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物 |
| HUE053705T2 (hu) | 2015-08-27 | 2021-07-28 | Pfizer | Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként |
| WO2017137334A1 (en) | 2016-02-08 | 2017-08-17 | F. Hoffmann-La Roche Ag | Spiroindolinones as ddr1 inhibitors |
| MX390141B (es) | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3787669A4 (en) | 2018-04-30 | 2022-03-30 | The Trustees of Indiana University | COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES |
| US11618746B2 (en) * | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| US20220144838A1 (en) | 2019-03-13 | 2022-05-12 | Nanjing Immunophage Biotech Co., Ltd. | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| TW202136219A (zh) | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Trpml調節劑 |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| IL296423A (en) | 2020-04-22 | 2022-11-01 | Anima Biotech Inc | Collagen 1 translation inhibitors and methods of use thereof |
| WO2021220178A1 (en) | 2020-04-29 | 2021-11-04 | Cominnex Zrt. | Iap antagonists and their therapeutic applications |
| JP2023524563A (ja) | 2020-05-07 | 2023-06-12 | ラムバム メド－テック リミテッド | Ａｐｏｌ１－関連疾患の治療に使用するための組成物 |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN115867532A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
| CN115996923B (zh) | 2020-08-26 | 2025-07-18 | 海思科医药集团股份有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US20230119114A1 (en) | 2021-08-26 | 2023-04-20 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitors and methods of using same |
| EP4440697A1 (en) | 2021-11-30 | 2024-10-09 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| AU2023219516A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
| CA3251050A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE |
| EP4476228A1 (en) | 2022-02-08 | 2024-12-18 | Vertex Pharmaceuticals Incorporated | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
| CN119212986A (zh) | 2022-02-08 | 2024-12-27 | 弗特克斯药品有限公司 | 作为apol1的抑制剂的螺哌啶衍生物及其使用方法 |
-
2021
- 2021-08-26 CN CN202180072946.7A patent/CN116547287B/zh active Active
- 2021-08-26 CR CR20230132A patent/CR20230132A/es unknown
- 2021-08-26 CA CA3190609A patent/CA3190609A1/en active Pending
- 2021-08-26 IL IL318169A patent/IL318169A/en unknown
- 2021-08-26 WO PCT/US2021/047754 patent/WO2022047031A1/en not_active Ceased
- 2021-08-26 AU AU2021333776A patent/AU2021333776A1/en active Pending
- 2021-08-26 JP JP2023513110A patent/JP7743504B2/ja active Active
- 2021-08-26 EP EP21773242.9A patent/EP4204423A1/en active Pending
- 2021-08-26 AR ARP210102407A patent/AR123355A1/es unknown
- 2021-08-26 IL IL300298A patent/IL300298B2/en unknown
- 2021-08-26 PE PE2023000722A patent/PE20231106A1/es unknown
- 2021-08-26 MX MX2023002269A patent/MX2023002269A/es unknown
- 2021-08-26 KR KR1020237008538A patent/KR20230057386A/ko active Pending
- 2021-08-26 UY UY0001039395A patent/UY39395A/es unknown
- 2021-08-26 US US17/446,135 patent/US11866446B2/en active Active
- 2021-08-26 BR BR112023003423A patent/BR112023003423A2/pt unknown
-
2023
- 2023-02-14 JO JOJO/P/2023/0035A patent/JOP20230035A1/ar unknown
- 2023-02-23 SA SA523442662A patent/SA523442662B1/ar unknown
- 2023-02-23 CL CL2023000536A patent/CL2023000536A1/es unknown
- 2023-02-28 DO DO2023000042A patent/DOP2023000042A/es unknown
- 2023-03-13 CO CONC2023/0003026A patent/CO2023003026A2/es unknown
- 2023-03-20 EC ECSENADI202320167A patent/ECSP23020167A/es unknown
- 2023-11-08 US US18/504,559 patent/US12421249B2/en active Active
-
2025
- 2025-09-10 JP JP2025150349A patent/JP2025183328A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023539194A (ja) | 2023-09-13 |
| PE20231106A1 (es) | 2023-07-19 |
| KR20230057386A (ko) | 2023-04-28 |
| BR112023003423A2 (pt) | 2023-03-21 |
| US20220106327A1 (en) | 2022-04-07 |
| IL300298B2 (en) | 2025-06-01 |
| JP2025183328A (ja) | 2025-12-16 |
| SA523442662B1 (ar) | 2025-05-26 |
| CN116547287B (zh) | 2025-09-26 |
| CA3190609A1 (en) | 2022-03-03 |
| CL2023000536A1 (es) | 2023-09-08 |
| IL300298A (en) | 2023-04-01 |
| JP7743504B2 (ja) | 2025-09-24 |
| AU2021333776A1 (en) | 2023-03-16 |
| EP4204423A1 (en) | 2023-07-05 |
| MX2023002269A (es) | 2023-05-16 |
| CN116547287A (zh) | 2023-08-04 |
| IL318169A (en) | 2025-03-01 |
| AR123355A1 (es) | 2022-11-23 |
| UY39395A (es) | 2022-03-31 |
| US11866446B2 (en) | 2024-01-09 |
| WO2022047031A1 (en) | 2022-03-03 |
| JOP20230035A1 (ar) | 2023-02-14 |
| CO2023003026A2 (es) | 2023-03-17 |
| CR20230132A (es) | 2023-06-27 |
| US20240368180A1 (en) | 2024-11-07 |
| IL300298B1 (en) | 2025-02-01 |
| DOP2023000042A (es) | 2023-07-09 |
| US12421249B2 (en) | 2025-09-23 |
| TW202227456A (zh) | 2022-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23020167A (es) | Inhibidores de apol1 y métodos para usar los mismos | |
| CL2024001586A1 (es) | Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y métodos para usar los mismos | |
| CO2024012060A2 (es) | Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos | |
| SA521422270B1 (ar) | Apol1 مثبطات لـ وطرق لاستخدامها | |
| CO2024000588A2 (es) | Composiciones y métodos para la inhibición de ras | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| CO2024012058A2 (es) | Derivados de 2-metil-4’,5’-dihidrospiro[piperidina-4,7’-tieno[2,3-c]pirano] como inhibidores de apol1 y métodos de uso de los mismos | |
| CL2025001163A1 (es) | Compuestos para tratar cáncer. | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| JOP20220227A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| UY39799A (es) | Compuestos de pirrolil–sulfonamida | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| AR125358A1 (es) | Inhibidores heteroaromáticos bicíclicos de la peptidasa 5 relacionada con la calicreína (klk5) | |
| BR112022005706A2 (pt) | Inibidores de 1,6-naftiridina substituída de cdk5 | |
| AR134197A1 (es) | Compuestos para el tratamiento de enfermedad renal | |
| AR057403A1 (es) | 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer | |
| AR131708A1 (es) | Protacts degradantes de kras a base de cereblon y usos relacionados con los mismos | |
| AR126554A1 (es) | Composiciones y métodos para la inhibición de ras | |
| AR119967A1 (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| EA202192859A1 (ru) | ПРОИЗВОДНЫЕ ТЕТРАГИДРО-1Н-ЦИКЛОПЕНТА[cd]ИНДЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА-2 (АЛЬФА), ИНДУЦИРУЕМОГО ГИПОКСИЕЙ | |
| EA202190787A1 (ru) | Пиридазиноны и способы их применения |